This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Although shares have fallen after the Q3 report, the stock still looks pricey at 33x forward earnings. Investors should consider waiting for earnings momentum to turn around before investing.
Abaxis, Inc. manufactures portable point-of-care blood analysis systems for use in veterinary and human patient-care settings.
Third Quarter Results
Abaxis reported disappointing Q3 earnings on October 22. Earnings per share came in at 18 cents, missing the Zacks Consensus Estimate of 20 cents. Earnings growth was flat compared with the same quarter last year.
Revenues rose 4% year-over-year to $45.9 million, which was short of the $48.0 million consensus. Total sales in the veterinary market were up 8% to $37.9 million.
Despite the increase in revenues, gross profit declined 5% as the gross margin fell 480 basis points to 47.7% of revenue. Total operating expenses improved 304 basis points, however, to 35.3% of revenues. But operating income still fell 9% year-over-year.
Following its second consecutive earnings miss, analysts revised their estimates meaningfully lower for Abaxis, as you can see in its 'Price & Consensus' chart:
It is a Zacks Rank #5 (Strong Sell) stock.
Based on consensus estimates, analysts project a 31% decline in EPS in 2013. But they expect a rebound in earnings in 2014 to $1.18, corresponding with 39% EPS growth.
Shares of Abaxis are down more than 6% since the Q3 earnings report. Despite the decline, the valuation picture still does not look attractive. Shares currently trade at a rich 33x 12-month forward earnings, well above the industry median of 23x. Its price to sales ratio of 4.1 is also well above its peers at 2.6.
The Bottom Line
With soft top-line growth, declining profit margins, falling earnings momentum and premium valuation, investors should wait to establish a position in Abaxis until its earnings momentum turns around.